Control of chronic pain by the ubiquitin-proteasome system in the spinal cord

Michael H. Ossipov, Igor Bazov, Luis R. Gardell, Justin Kowal, Tatiana Yakovleva, Ivan Usynin, Tomas J. Ekström, Frank Porreca, Georgy Bakalkin

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Chronic pain is maintained in part by long-lasting neuroplastic changes in synapses and several proteins critical for synaptic plasticity are degraded by the ubiquitin-proteasome system (UPS). Here, we show that proteasome inhibitors administered intrathecally or subcutaneously prevented the development and reversed nerve injury-induced pain behavior. They also blocked pathological pain induced by sustained administration of morphine or spinal injection of dynorphin A, an endogenous mediator of chronic pain. Proteasome inhibitors blocked mechanical allodynia and thermal hyperalgesia in all three pain models although they did not modify responses to mechanical stimuli, but partially inhibited responses to thermal stimuli in control rats. In the spinal cord, these compounds abolished the enhanced capsaicin-evoked calcitonin gene-related peptide (CGRP) release and dynorphin A upregulation, both elicited by nerve injury. Model experiments demonstrated that the inhibitors may act directly on dynorphin-producing cells, blocking dynorphin secretion. Thus, the effects of proteasome inhibitors on chronic pain were apparently mediated through several cellular mechanisms indispensable for chronic pain, including those of dynorphin A release and postsynaptic actions, and of CGRP secretion. Levels of several UPS proteins were reduced in animals with neuropathic pain, suggesting that UPS downregulation, like effects of proteasome inhibitors, counteracts the development of chronic pain. The inhibitors did not produce marked or disabling motor disturbances at doses that were used to modify chronic pain. These results suggest that the UPS is a critical intracellular regulator of pathological pain, and that UPS-mediated protein degradation is required for maintenance of chronic pain and nociceptive, but not non-nociceptive responses in normal animals.

Original languageEnglish (US)
Pages (from-to)8226-8237
Number of pages12
JournalJournal of Neuroscience
Volume27
Issue number31
DOIs
StatePublished - Aug 1 2007

Fingerprint

Proteasome Endopeptidase Complex
Ubiquitin
Chronic Pain
Dynorphins
Spinal Cord
Proteasome Inhibitors
Hyperalgesia
Pain
Calcitonin Gene-Related Peptide
Spinal Injections
Neuronal Plasticity
Capsaicin
Wounds and Injuries
Neuralgia
Synapses
Morphine
Proteolysis
Proteins
Up-Regulation
Down-Regulation

Keywords

  • Dynorphin
  • Epoxomicin
  • Pain
  • Plasticity
  • Proteasome
  • Treatment

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Ossipov, M. H., Bazov, I., Gardell, L. R., Kowal, J., Yakovleva, T., Usynin, I., ... Bakalkin, G. (2007). Control of chronic pain by the ubiquitin-proteasome system in the spinal cord. Journal of Neuroscience, 27(31), 8226-8237. https://doi.org/10.1523/JNEUROSCI.5126-06.2007

Control of chronic pain by the ubiquitin-proteasome system in the spinal cord. / Ossipov, Michael H.; Bazov, Igor; Gardell, Luis R.; Kowal, Justin; Yakovleva, Tatiana; Usynin, Ivan; Ekström, Tomas J.; Porreca, Frank; Bakalkin, Georgy.

In: Journal of Neuroscience, Vol. 27, No. 31, 01.08.2007, p. 8226-8237.

Research output: Contribution to journalArticle

Ossipov, MH, Bazov, I, Gardell, LR, Kowal, J, Yakovleva, T, Usynin, I, Ekström, TJ, Porreca, F & Bakalkin, G 2007, 'Control of chronic pain by the ubiquitin-proteasome system in the spinal cord', Journal of Neuroscience, vol. 27, no. 31, pp. 8226-8237. https://doi.org/10.1523/JNEUROSCI.5126-06.2007
Ossipov MH, Bazov I, Gardell LR, Kowal J, Yakovleva T, Usynin I et al. Control of chronic pain by the ubiquitin-proteasome system in the spinal cord. Journal of Neuroscience. 2007 Aug 1;27(31):8226-8237. https://doi.org/10.1523/JNEUROSCI.5126-06.2007
Ossipov, Michael H. ; Bazov, Igor ; Gardell, Luis R. ; Kowal, Justin ; Yakovleva, Tatiana ; Usynin, Ivan ; Ekström, Tomas J. ; Porreca, Frank ; Bakalkin, Georgy. / Control of chronic pain by the ubiquitin-proteasome system in the spinal cord. In: Journal of Neuroscience. 2007 ; Vol. 27, No. 31. pp. 8226-8237.
@article{f3ea2656baf7448c8d5ca5cc75ce824a,
title = "Control of chronic pain by the ubiquitin-proteasome system in the spinal cord",
abstract = "Chronic pain is maintained in part by long-lasting neuroplastic changes in synapses and several proteins critical for synaptic plasticity are degraded by the ubiquitin-proteasome system (UPS). Here, we show that proteasome inhibitors administered intrathecally or subcutaneously prevented the development and reversed nerve injury-induced pain behavior. They also blocked pathological pain induced by sustained administration of morphine or spinal injection of dynorphin A, an endogenous mediator of chronic pain. Proteasome inhibitors blocked mechanical allodynia and thermal hyperalgesia in all three pain models although they did not modify responses to mechanical stimuli, but partially inhibited responses to thermal stimuli in control rats. In the spinal cord, these compounds abolished the enhanced capsaicin-evoked calcitonin gene-related peptide (CGRP) release and dynorphin A upregulation, both elicited by nerve injury. Model experiments demonstrated that the inhibitors may act directly on dynorphin-producing cells, blocking dynorphin secretion. Thus, the effects of proteasome inhibitors on chronic pain were apparently mediated through several cellular mechanisms indispensable for chronic pain, including those of dynorphin A release and postsynaptic actions, and of CGRP secretion. Levels of several UPS proteins were reduced in animals with neuropathic pain, suggesting that UPS downregulation, like effects of proteasome inhibitors, counteracts the development of chronic pain. The inhibitors did not produce marked or disabling motor disturbances at doses that were used to modify chronic pain. These results suggest that the UPS is a critical intracellular regulator of pathological pain, and that UPS-mediated protein degradation is required for maintenance of chronic pain and nociceptive, but not non-nociceptive responses in normal animals.",
keywords = "Dynorphin, Epoxomicin, Pain, Plasticity, Proteasome, Treatment",
author = "Ossipov, {Michael H.} and Igor Bazov and Gardell, {Luis R.} and Justin Kowal and Tatiana Yakovleva and Ivan Usynin and Ekstr{\"o}m, {Tomas J.} and Frank Porreca and Georgy Bakalkin",
year = "2007",
month = "8",
day = "1",
doi = "10.1523/JNEUROSCI.5126-06.2007",
language = "English (US)",
volume = "27",
pages = "8226--8237",
journal = "Journal of Neuroscience",
issn = "0270-6474",
publisher = "Society for Neuroscience",
number = "31",

}

TY - JOUR

T1 - Control of chronic pain by the ubiquitin-proteasome system in the spinal cord

AU - Ossipov, Michael H.

AU - Bazov, Igor

AU - Gardell, Luis R.

AU - Kowal, Justin

AU - Yakovleva, Tatiana

AU - Usynin, Ivan

AU - Ekström, Tomas J.

AU - Porreca, Frank

AU - Bakalkin, Georgy

PY - 2007/8/1

Y1 - 2007/8/1

N2 - Chronic pain is maintained in part by long-lasting neuroplastic changes in synapses and several proteins critical for synaptic plasticity are degraded by the ubiquitin-proteasome system (UPS). Here, we show that proteasome inhibitors administered intrathecally or subcutaneously prevented the development and reversed nerve injury-induced pain behavior. They also blocked pathological pain induced by sustained administration of morphine or spinal injection of dynorphin A, an endogenous mediator of chronic pain. Proteasome inhibitors blocked mechanical allodynia and thermal hyperalgesia in all three pain models although they did not modify responses to mechanical stimuli, but partially inhibited responses to thermal stimuli in control rats. In the spinal cord, these compounds abolished the enhanced capsaicin-evoked calcitonin gene-related peptide (CGRP) release and dynorphin A upregulation, both elicited by nerve injury. Model experiments demonstrated that the inhibitors may act directly on dynorphin-producing cells, blocking dynorphin secretion. Thus, the effects of proteasome inhibitors on chronic pain were apparently mediated through several cellular mechanisms indispensable for chronic pain, including those of dynorphin A release and postsynaptic actions, and of CGRP secretion. Levels of several UPS proteins were reduced in animals with neuropathic pain, suggesting that UPS downregulation, like effects of proteasome inhibitors, counteracts the development of chronic pain. The inhibitors did not produce marked or disabling motor disturbances at doses that were used to modify chronic pain. These results suggest that the UPS is a critical intracellular regulator of pathological pain, and that UPS-mediated protein degradation is required for maintenance of chronic pain and nociceptive, but not non-nociceptive responses in normal animals.

AB - Chronic pain is maintained in part by long-lasting neuroplastic changes in synapses and several proteins critical for synaptic plasticity are degraded by the ubiquitin-proteasome system (UPS). Here, we show that proteasome inhibitors administered intrathecally or subcutaneously prevented the development and reversed nerve injury-induced pain behavior. They also blocked pathological pain induced by sustained administration of morphine or spinal injection of dynorphin A, an endogenous mediator of chronic pain. Proteasome inhibitors blocked mechanical allodynia and thermal hyperalgesia in all three pain models although they did not modify responses to mechanical stimuli, but partially inhibited responses to thermal stimuli in control rats. In the spinal cord, these compounds abolished the enhanced capsaicin-evoked calcitonin gene-related peptide (CGRP) release and dynorphin A upregulation, both elicited by nerve injury. Model experiments demonstrated that the inhibitors may act directly on dynorphin-producing cells, blocking dynorphin secretion. Thus, the effects of proteasome inhibitors on chronic pain were apparently mediated through several cellular mechanisms indispensable for chronic pain, including those of dynorphin A release and postsynaptic actions, and of CGRP secretion. Levels of several UPS proteins were reduced in animals with neuropathic pain, suggesting that UPS downregulation, like effects of proteasome inhibitors, counteracts the development of chronic pain. The inhibitors did not produce marked or disabling motor disturbances at doses that were used to modify chronic pain. These results suggest that the UPS is a critical intracellular regulator of pathological pain, and that UPS-mediated protein degradation is required for maintenance of chronic pain and nociceptive, but not non-nociceptive responses in normal animals.

KW - Dynorphin

KW - Epoxomicin

KW - Pain

KW - Plasticity

KW - Proteasome

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=34547654170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547654170&partnerID=8YFLogxK

U2 - 10.1523/JNEUROSCI.5126-06.2007

DO - 10.1523/JNEUROSCI.5126-06.2007

M3 - Article

C2 - 17670969

AN - SCOPUS:34547654170

VL - 27

SP - 8226

EP - 8237

JO - Journal of Neuroscience

JF - Journal of Neuroscience

SN - 0270-6474

IS - 31

ER -